Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): RFA DD 10-002 Public Health Research on Spina Bifida, RFA DD 10-003 Public Health Research on Children and Adults Living With Spina Bifida, RFA DD 10-004 Developing a Prospective Assessment of the Development, Health, and Condition Progression in Young Children With Spina Bifida,and RFA DP 10-006 Epidemiologic Study of Inflammatory Bowel Disease, Initial Review, 13560 [2010-6178]

Download as PDF 13560 Federal Register / Vol. 75, No. 54 / Monday, March 22, 2010 / Notices FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Paul Tran at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/ AdvisoryCommittees/AboutAdvisory Committees/ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry. Dated: March 16, 2010. Jill Hartzler Warner, Acting Associate Commissioner for Special Medical Programs. Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Surveillance, Natural History, Quality of Care and Outcomes of Diabetes Mellitus With Onset in Childhood and Adolescence, RFA DP 10–001, Initial Review [FR Doc. 2010–6169 Filed 3–19–10; 8:45 am] BILLING CODE 4160–01–S Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Knowledge Synthesis Center for Evaluating Genomic Application in Practice and Prevention, GD 10–001, Initial Review pwalker on DSK8KYBLC1PROD with NOTICES In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 10 a.m.–5 p.m., May 25, 2010 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Knowledge Synthesis Center for Evaluating Genomic Application in Practice and Prevention, GD 10–001.’’ Contact Person for More Information: Donald Blackman, PhD, Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, Office of the Director, Extramural Research Program Office, 4770 Buford Highway, NE., Mailstop K–92, Atlanta, GA 30341, Telephone: (770) 488–3023, E-mail: DBY7@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices 16:41 Mar 19, 2010 Jkt 220001 [FR Doc. 2010–6194 Filed 3–19–10; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): RFA DD 10–002 Public Health Research on Spina Bifida, RFA DD 10–003 Public Health Research on Children and Adults Living With Spina Bifida, RFA DD 10– 004 Developing a Prospective Assessment of the Development, Health, and Condition Progression in Young Children With Spina Bifida,and RFA DP 10–006 Epidemiologic Study of Inflammatory Bowel Disease, Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 10 a.m.–5 p.m., May 27, 2010 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of ‘‘Surveillance, Natural History, Quality of Care and Outcomes of Diabetes Mellitus With Onset in Childhood and Adolescence, RFA DP 10–001.’’ For More Information Contact: Donald Blackman, PhD, Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, Office of the Director, Extramural Research Program Office, 4770 Buford Highway, NE., Mailstop K–92, Atlanta, GA 30341, Telephone: (770) 488–3023, E-mail: DBY7@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry. Time and Date: 9 a.m.–4 p.m., April 15, 2010 (Closed) Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of ‘‘RFA DD 10–002 Public Health Research on Spina Bifida, RFA DD 10–003 Public Health Research on Children and Adults Living with Spina Bifida, RFA DD 10– 004 Developing a Prospective Assessment of the Development, Health, and Condition Progression in Young Children with Spina Bifida, and RFA DP 10–006 Epidemiologic Study of Inflammatory Bowel Disease.’’ Contact Person for More Information: Donald Blackman, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, Office of the Director, Extramural Research Program Office, 4770 Buford Highway, NE., Mailstop K–92, Atlanta, GA 30341, Telephone: (770) 488–3023, Email: DBY7@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: March 12, 2010. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. Dated: March 12, 2010. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2010–6180 Filed 3–19–10; 8:45 am] [FR Doc. 2010–6178 Filed 3–23–10; 8:45 am] BILLING CODE 4163–18–P BILLING CODE 4163–18–P In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Nov<24>2008 Dated: March 12, 2010. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Frm 00078 Fmt 4703 Sfmt 9990 E:\FR\FM\22MRN1.SGM 22MRN1

Agencies

[Federal Register Volume 75, Number 54 (Monday, March 22, 2010)]
[Notices]
[Page 13560]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-6178]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): RFA DD 10-002 Public Health Research on Spina 
Bifida, RFA DD 10-003 Public Health Research on Children and Adults 
Living With Spina Bifida, RFA DD 10-004 Developing a Prospective 
Assessment of the Development, Health, and Condition Progression in 
Young Children With Spina Bifida,and RFA DP 10-006 Epidemiologic Study 
of Inflammatory Bowel Disease, Initial Review

    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting:

    Time and Date: 9 a.m.-4 p.m., April 15, 2010 (Closed)
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters To Be Discussed: The meeting will include the initial 
review, discussion, and evaluation of ``RFA DD 10-002 Public Health 
Research on Spina Bifida, RFA DD 10-003 Public Health Research on 
Children and Adults Living with Spina Bifida, RFA DD 10-004 
Developing a Prospective Assessment of the Development, Health, and 
Condition Progression in Young Children with Spina Bifida, and RFA 
DP 10-006 Epidemiologic Study of Inflammatory Bowel Disease.''
    Contact Person for More Information: Donald Blackman, Ph.D., 
Scientific Review Officer, National Center for Chronic Disease 
Prevention and Health Promotion, Office of the Director, Extramural 
Research Program Office, 4770 Buford Highway, NE., Mailstop K-92, 
Atlanta, GA 30341, Telephone: (770) 488-3023, Email: DBY7@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both CDC and the Agency for Toxic Substances and 
Disease Registry.

    Dated: March 12, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2010-6178 Filed 3-23-10; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.